Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Radiation - Dose Level 4 Clear all
Completed Phase 3 Interventional

SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed

NCT00002551
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, levamisole hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2008
U.S. locations
35
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Sep 23, 2026, 5:46 PM EDT
Active, not recruiting Not applicable Interventional

Preoperative Irradiation for Stage I Breast Cancer

NCT05464667
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation Therapy (RT)
Radiation
Lead sponsor
Parul Barry
Other
Eligibility
50 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 23, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

NCT03807765
View directory record Official record
Conditions
Metastatic Breast Cancer, Brain Metastases
Interventions
Nivolumab, Stereotactic Radiosurgery
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 23, 2026, 5:46 PM EDT
Terminated Phase 1 Interventional

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

NCT04892264
View directory record Official record
Conditions
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Belantamab Mafodotin, Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Biospecimen Collection, Skeletal Survey X-Ray, Low Dose Computed Tomography of the Whole Body, Bone Marrow Aspiration, Bone Marrow Biopsy
Biological · Drug · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 23, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation

NCT00201799
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Infliximab
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
20 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 23, 2026, 5:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis

NCT00622895
View directory record Official record
Conditions
Systemic Scleroderma, Severe Systemic Sclerosis
Interventions
fludarabine phosphate, Mycophenolic Acid, tacrolimus, total-body irradiation, bone marrow transplantation, reduced intensity allogeneic hematopoietic stem cell transplantation, quality-of-life assessment, laboratory biomarker analysis, flow cytometry, biopsy
Drug · Radiation · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
2
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 23, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

NCT03434730
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Myeloproliferative Disorder, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia
Interventions
Total Body Irradiation, Cyclosporine, Mycophenolate Mofetil, Tocilizumab, Filgrastim
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 23, 2026, 5:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND)
Biological · Other · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 23, 2026, 5:46 PM EDT
Withdrawn Phase 2 Interventional

A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma

NCT06994299
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Radiation Therapy, Tremelimumab, Durvalumab, Surgery
Radiation · Drug · Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 23, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin

NCT00386100
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Avandamet 6 mg/1500 mg (ttd), Avandamet 4 mg/1000 mg (ttd), Avandamet 2 mg/500 mg (ttd), Avandamet 8 mg/ 2000 mg (ttd), Metformin 500 mg (ttd), Metformin 1000 mg (ttd), Metformin 1500 mg (ttd), Metformin 2000 mg (ttd)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
71
States / cities
Tuscaloosa, Alabama • Gilbert, Arizona • Glendale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 23, 2026, 5:46 PM EDT
Recruiting Phase 2 Interventional

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

NCT06315309
View directory record Official record
Conditions
GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions
ATG Combined with Tacrolimus and Mini Methotrexate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 23, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

NCT01319565
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine, Young TIL, Total Body Irradiation (TBI)
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 66 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 23, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer

NCT00142506
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction
Interventions
sildenafil citrate and questionaires, placebo tablets and questionaires
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Sep 23, 2026, 5:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen

NCT00556452
View directory record Official record
Conditions
Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Clofarabine/Busulfan x 4, Peripheral blood stem cell transplant, Total Lymphoid Irradiation
Drug · Procedure · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 23, 2026, 5:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

NCT04287868
View directory record Official record
Conditions
Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
Interventions
PDS0101, M7824, NHS-IL12
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 23, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

NCT02496585
View directory record Official record
Conditions
Lung Cancer, Lung Metastases
Interventions
Nintedanib, Prednisone, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
12
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 23, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue

NCT01944215
View directory record Official record
Conditions
Molecular Imaging
Interventions
Meal, Exercise, Sestamibi, Caffeine Tablet, External Heating
Dietary Supplement · Other · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 23, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer

NCT04690855
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Talazoparib, Atezolizumab, Radiation
Drug · Radiation
Lead sponsor
Mylin A. Torres, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 23, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

NCT03939689
View directory record Official record
Conditions
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate, Progressive mCRPC
Interventions
I-131-1095, Enzalutamide
Drug
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 23, 2026, 5:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

NCT01770418
View directory record Official record
Conditions
Lung Neoplasms
Interventions
Radiation with Concurrent Chemotherapy
Radiation
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
6
States / cities
Jacksonville, Florida • Warrenville, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 23, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

NCT01532635
View directory record Official record
Conditions
Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Lymphocytic Leukemia, CLL, Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma, Myeloma
Interventions
Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY), Tacrolimus, Mycophenolate Mofetil (MMF), Hematopoietic Stem Cell Transplant (HSCT)
Radiation · Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 23, 2026, 5:46 PM EDT
Terminated Phase 1 Interventional

Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation Therapy

NCT00788307
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ad5-CMV-NIS, Liothyronine Sodium, Reverse Transcriptase Polymerase Chain Reaction, laboratory biomarker analysis, Iodine I 131, Iodine I 123
Biological · Drug · Genetic + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 23, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma

NCT00002571
View directory record Official record
Conditions
Lymphoma
Interventions
bleomycin sulfate, filgrastim, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, trimethoprim-sulfamethoxazole, vincristine sulfate, radiation therapy, Intrathecal cytarabine
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
85
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 23, 2026, 5:46 PM EDT
Terminated Not applicable Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer

NCT02388932
View directory record Official record
Conditions
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma, Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Hypopharyngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Hypopharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Hypopharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVC Oral Cavity Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions
Stereotactic Body Radiation Therapy, Positron Emission Tomography, Computed Tomography, Quality-of-Life Assessment
Radiation · Device · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Sep 23, 2026, 5:46 PM EDT